{"path":"Images/Pasted image 20240318083442.png","text":"[Drugs used for treatment of pulmonary arterial hypertension (Group 1 Comment Calcium channel blockers [e.g., Amlodipine Only iPAH, if vasoreactivity testing s positive Endothelin receptor antagonists |Ambrisentan | Hepatic toxicity; mainly replaced by Macitentan Phosphodiesterase type 5 inhibitors |Sildenafil Both: no combination with NO donors (NO pathway) Tadalafil and guanylate cyclase stimulators [Guanylate cyclase stimulators No combination with NO donors and (NO pathway) phosphodiesterase type 5 inhibitors; also approved for Group 4 (CTEPH) Prostacyclin analogues Epoprostenol (intravenous) lioprost (inhaled) Treprostinil (subcutaneous) | Intravenous, if the subcutaneous form is not tolerated [ 1 Prostacyclin IP receptor agonists _|Selexipag (oral) â€˜Approved in the EU since May 2016","libVersion":"0.3.2","langs":"eng"}